Highlights
- Biologics to contribute 52%of the Top 100 product sales by 2022; Roche leads market
- Roche gains the top spot of the pipeline value creation ranking proving its leadership ambitions beyond oncology. AstraZeneca and AbbVie complete the podium
- NovoNordisk’s portfolio expected to yield the highest return on investment in the future
- Biogen’s aducanumab and J&J’s apalutamide projected to be the most valuable R&D projects
- Worldwide pharmaceutical R&D spend expected togrow by 2.4%(CAGR)to $181bn in 2022
- Average R&D spend per NME at $4 bn over the last 10 years
- Roche forecast to be the biggest spender on pharmaceutical R&D in 2022.
- New drug approvals in2016 drop to 27 NMEs down 50% vs. the record high of 56 in 2015. Positive trend in the rst 5 months of 2017 with 21 NMEs already approved
- Oncology is still the largest therapy are a in sales (+12.7%CAGR) 2016-22
- Roche remains atop the oncology eldbutits leadership is challenged by Celgene. Novartis to drop out of the top 3
- NovoNordisk is expected to remain the major player in the anti-diabetics market in 2022, but Lilly is gaining ground behind driven by Trulicity
- AbbVie still dominates anti-rheumatics market in 2022;ABT-494(upadacitinib) set to be the most promising R&D asset in development
- GSK leads in the vaccine market a head of Merck and Pfizer
- Pfizer’s pneumococcal vaccine Prevnar 13 remains the top selling vaccine product
- Gilead lead continues in anti-viral market in 2022 largely due to its HIV portfolio
- Opdivo and Revlimid to compete for the top selling products in the world in 2022
- Humira still expected to be the top selling drug in 2022 at $15.9bn a headof Revlimid and Opdivo
- Keytruda ($9.5bnin2022) nearly closed the gap with Opdivo ($9.9bn) interms of consensus forecast
- Eliquis took over Xareltoas the leading anti-coagulant in 2022 at $8.5bn
- AbbVie’s Humira will continue to be the leading product in the USA in 2022, with sales of $12.0bn. Keytruda knocks o Opdivo as the top-selling PD-1/PD-L1 product in 2022
World Preview 2017, Outlook to 2022
